ONC-392 is under clinical development by OncoC4 and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ONC-392’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONC-392 is under development for the treatment of metastatic solid tumors like malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, cervical cancer, colorectal cancer, sarcoma, peritoneal cancer, fallopian tube cancer, adenoid cystic carcinoma, esophageal cancer, anal canal cancer and unspecified indication. The drug candidate is a monoclonal antibody. It is administered through intravenous route. It acts by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
It was also under development for the treatment of Merkel cell carcinoma.
OncoC4 is a biopharmaceutical company, provides oncology-related services. It is headquartered in Maryland, the US.
For a complete picture of ONC-392’s drug-specific PTSR and LoA scores, buy the report here.